Submission declined on 11 April 2026 by Lynch44 (talk). This draft's references do not show that the person meets Wikipedia's criteria for inclusion for people. The draft requires multiple published secondary sources that: provide significant coverage: discuss the person in detail, not brief mentions or interviews lacking independent analysis; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the person, such as interviews, press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by Lynch44 57 days ago. Last edited by Bonadea 32 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: Sources written by the subject (or by organizations affiliated with the subject) do not count towards notability. Lynch44 17:11, 11 April 2026 (UTC)

• Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Rdacey0606 (talk) 15:24, 11 April 2026 (UTC)

Robert M. Roth is an American biotechnology executive and inventor. He has held leadership roles at Apath, LLC, focused on antiviral drug discovery technologies (particularly for hepatitis C virus), and at BioActive Technology, LLC, involved in bioactive polymer coatings for air filtration.

Roth earned a Bachelor of Science in biology from Creighton University (1988–1993) and a Master of Biology in health sciences and virology from Washington University School of Medicine in St. Louis (1993–1996). He holds a Global Executive MBA in business administration and management from Duke University's Fuqua School of Business (2011–2013) and a Certificate of Professional Development in business administration and management from The Wharton School (2010–2011).

Roth is a Diplomate in Pharmaceutical Toxicology certified by the American Board of Toxicology (2006–2012) and was a member of the American Association of Pharmaceutical Scientists (2005–2009).

Roth joined Apath, LLC in 1999. He served as vice president of strategic operations and later as president and chief executive officer. His work at Apath centered on high-throughput screening systems using replication-competent and subgenomic viral models for antiviral drug discovery, targeting viruses including hepatitis C (HCV), West Nile, RSV, Ebola, and influenza. Materials and cell lines from Apath, such as HUH 7.5 cells, have supported external virology research, including coronavirus vaccine studies as recently as 2025.

Apath was founded by Charles M. Rice, who shared the 2020 Nobel Prize in Physiology or Medicine for discoveries concerning the hepatitis C virus. Roth has been listed as a collaborator with Rice in international HCV research networks, including the Pawlotsky Research Lab (INSERM U955) for genotypic and phenotypic studies of hepatitis virus resistance to antivirals.^[1]

In 2012, Southern Research announced a collaboration with Apath to provide fee-for-service preclinical testing using Apath's HCV technology; Roth was quoted regarding the agreement and the company's sublicensing efforts.

Roth has been involved in a Department of Defense-funded project at Apath for the development of new antiviral drugs targeting Ebola infection.

Prior to Apath, he worked at Genome Systems and Incyte Genomics on high-throughput screening systems, integrated robotics platforms, and laboratory management.

Apath, LLC concluded all business operations effective May 31, 2025.

Roth has also served as a biotechnology executive and managing director with BioActive Technology, LLC. He contributed to the development team for the ViSTAT Advanced Pathogen Defense platform, which applies ablative polymer coatings to air filtration media to inactivate airborne pathogens. A 2026 medRxiv preprint describes the technology's performance in converting passive filters into active biofiltration surfaces.

Roth is a co-author on peer-reviewed research identifying small-molecule inhibitors of viral replication. This includes a 2014 study (published in Antimicrobial Agents and Chemotherapy) identifying AP80978, a novel inhibitor of hepatitis C virus replication that targets the NS4B protein,^[2] a 2007 study on novel small-molecule inhibitors of West Nile virus infection,^[3] and a 2006 conference paper on identification of inhibitors of Ebola virus using a subgenomic replication system.^[4]

In 2004, Roth served on the National Institutes of Health (NIH) Working Group for Drug-Induced Liver Disease, contributing to the trans-NIH Action Plan for Liver Disease Research.^[5]

He is named as an inventor on multiple patents related to antiviral technologies, including:

• US20110262397A1 / US8809344B2 on tetrahydropyrazolo[1,5-a]pyrimidine compounds, compositions, and methods for control of hepatitis C viral infections (assigned to Apath, LLC)^[6]
• WO2006093518A2 on thienyl compounds for treating virus-related conditions (assigned to Apath, LLC)
• Patents on multiple virus replicon culture systems, 4-aminoquinoline compounds, and air filters with ablative and sacrificial polymers (associated with the ViSTAT platform)